IL-2 Mutein Therapies Market Expected to Approach $1.43 Billion by 2030

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Interleukin-2 (IL-2) Mutein Therapies Market During 2026–2030?

The interleukin-2 (il-2) mutein therapies market size has seen swift growth in recent years. It is projected to expand from $0.73 billion in 2025 to $0.84 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.1%. The expansion observed in the past can be attributed to progress in cytokine engineering techniques, a deeper comprehension of immune signaling pathways, the initial clinical achievements of modified IL-2 therapies, increased investment in immuno-oncology research, and the rising occurrence of immune-mediated diseases.

The interleukin-2 (il-2) mutein therapies market is anticipated to experience substantial expansion in the forthcoming years. Its size is projected to reach $1.43 billion in 2030, reflecting a compound annual growth rate (CAGR) of 14.4%. This expected growth during the forecast period stems from various factors, including the broader adoption of personalized immunotherapy approaches, intensified clinical trial activity for next-generation cytokines, an escalating demand for safer immune modulators, increasing regulatory backing for innovative biologics, and a rise in partnerships between biotech and pharma companies. Prominent trends observed within this period involve the increasing development of receptor-biased il-2 muteins, a heightened focus on reducing cytokine toxicity profiles, the growing utilization of combination immunotherapy regimens, the expansion of precision immune modulation strategies, and enhanced clinical pipeline activities for autoimmune and oncology indications.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33185&type=smp

What Drivers Are Influencing The Interleukin-2 (IL-2) Mutein Therapies Market?

Heightened demand for targeted immunotherapies is anticipated to fuel expansion within the interleukin-2 (IL-2) mutein therapies market. These immunotherapies represent treatments crafted to adjust the immune system, allowing it to specifically target cancer cells and simultaneously reduce harm to healthy tissues. The need for such therapies is escalating because healthcare professionals and researchers are searching for safer, more potent options compared to traditional chemotherapy and radiation therapy, which frequently carry substantial toxicity and lack precise targeting. IL-2 mutein therapies facilitate the progress of targeted immunotherapies through their use of engineered interleukin-2 variants that preferentially activate immune effector cells crucial for anti-tumor responses, concurrently diminishing the stimulation of pathways linked to widespread toxicity. A notable example is that in April 2025, the Cancer Research Institute, a US-based non-profit organization, reported that FDA approvals encompassed 17 novel targeted immunotherapy agents in 2024, thereby broadening the available choices for targeted immune-based cancer treatment and enlarging the population of patients who can benefit from these therapies. Consequently, the expanding demand for targeted immunotherapies is a primary factor propelling the growth of the interleukin-2 (IL-2) mutein therapies market.

How Are The Various Segments Of The Interleukin-2 (IL-2) Mutein Therapies Market Categorized?

The interleukin-2 (il-2) mutein therapies market covered in this report is segmented –

1) By Product Type: Monotherapy; Combination Therapy

2) By Route Of Administration: Intravenous; Subcutaneous; Other Route Of Administrations

3) By Application: Cancer; Autoimmune Diseases; Infectious Diseases; Other Applications

4) By End User: Hospitals; Specialty Clinics; Research Institutes; Other End Users

Subsegments:

1) By Monotherapy: Single Agent Interleukin Two Mutein Therapy; Standalone Cytokine Based Immunotherapy; Targeted Immune Modulation Therapy

2) By Combination Therapy: Interleukin Two Mutein With Immune Checkpoint Inhibitors; Interleukin Two Mutein With Chemotherapy; Interleukin Two Mutein With Targeted Biologic Therapies; Interleukin Two Mutein With Cell Based Therapies

What Trends Are Affecting The Expansion Of The Interleukin-2 (IL-2) Mutein Therapies Market?

Companies operating in the interleukin-2 (IL-2) mutein therapies market are increasingly prioritizing technological advancements in cytokine-based immunotherapy, specifically the selective activation of regulatory T-cells (Tregs) through engineered IL-2 muteins. This selective regulatory T-cell activation using engineered IL-2 muteins involves the application of genetically modified IL-2 proteins, designed to predominantly stimulate Tregs while limiting the activation of effector immune cells. For example, in December 2023, Almirall S.A., a Spain-based pharmaceutical company, launched its first Phase I clinical study for its engineered IL-2 mutein fusion protein, ALM223, with the goal of evaluating its safety, pharmacokinetics, immunogenicity, and pharmacodynamics in autoimmune diseases. This candidate possesses selective Treg activation capabilities, a modified Fc fusion designed to enhance molecular stability, and an engineered cytokine backbone aimed at optimizing immune modulation. While these technological strides underscore the promise of IL-2 muteins in achieving targeted immunomodulation and broader applicability in autoimmune conditions, their clinical efficacy and long-term safety profiles must still be established through ongoing and future trials.

Which Companies Are Expanding Their Footprint In The Interleukin-2 (IL-2) Mutein Therapies Market?

Major companies operating in the interleukin-2 (il-2) mutein therapies market are Merck & Co. Inc., Sanofi S.A., Roche Holding AG, Bristol-Myers Squibb, Amgen Inc., Lonza Group AG, Alkermes plc, BioNTech SE, Xencor Inc., Innovent Biologics Inc., Ascendis Pharma A/S, ShanghAI Junshi Biosciences Co. Ltd., Mural Oncology Inc., ProBioGen AG, Werewolf Therapeutics Ltd., Philogen S.p.A., Cue Biopharma Inc., Medicenna Therapeutics Corp., Bright Peak Therapeutics Inc., Iovance Biotherapeutics Inc.

Read the full interleukin-2 (il-2) mutein therapies market report here:

https://www.thebusinessresearchcompany.com/report/interleukin-2-il-2-mutein-therapies-market-report

Which Regions Are Poised For Strategic Growth In The Interleukin-2 (IL-2) Mutein Therapies Market?

North America was the largest region in the interleukin 2 (IL-2) mutein therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the interleukin-2 (il-2) mutein therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Interleukin-2 (IL-2) Mutein Therapies Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=33185&type=smp

Browse Through More Reports Similar to the Global Interleukin-2 (IL-2) Mutein Therapies Market 2026, By The Business Research Company

Artificial Intelligence Ai Studio Market Report 2026

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-studio-global-market-report

Ai Content Marketing Market Report 2026

https://www.thebusinessresearchcompany.com/report/ai-content-marketing-global-market-report

Artificial Intelligence Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795